Hepatotoxicity Due to Antibiotics

Clinics in Liver Disease

Volumn 11, Issue 3, 2007, Pages 549-561

  Polson, Julie E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ARYLAMINE ACETYLTRANSFERASE; BETA LACTAM ANTIBIOTIC; CARBON TETRACHLORIDE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMAZINE; COTRIMOXAZOLE; DICLOXACILLIN; ERYTHROMYCIN; FLUCLOXACILLIN; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MINOCYCLINE; NITROFURANTOIN; OXACILLIN; PYRAZINAMIDE; RIFAMPICIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ACUTE HEPATITIS; ANAMNESIS; AUTOIMMUNE DISEASE; BIOCHEMISTRY; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG CLEARANCE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EOSINOPHILIA; FATTY LIVER; GENETIC POLYMORPHISM; GROUPS BY AGE; HUMAN; KIDNEY DYSFUNCTION; LIVER FAILURE; LIVER GRANULOMA; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LUNG INJURY; LYMPHADENOPATHY; MONOTHERAPY; PANCREATITIS; PATHOGENESIS; PATIENT MONITORING; PROGNOSIS; RARE DISEASE; REVIEW; RISK FACTOR; SEX RATIO; STEATOSIS; SYMPTOMATOLOGY;

ANTI-BACTERIAL AGENTS; HUMANS; LIVER DISEASES; RISK FACTORS;

EID: 34548130665     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.06.009     Document Type: Review

References (53)

1. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd edition (1999), Lippincott Williams & Wilkins, Philadelphia
2. Forget E.J., and Menzies D. Adverse reactions to first-line antituberculous drugs. Expert Opin Drug Saf 5 (2006) 231-249
3. Temple RJ. Hepatotoxicity through the years: impact on the FDA. Available at: http://www.fda.gov/cder/livertox/Presentations/im1389/sld002.htm. Accessed April 9, 2007.
4. Aithal G.P., Rawlins M.D., and Day C.P. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 319 (1999) 1541-1544
5. Meier Y., Cavallaro M., Roos M., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 61 (2005) 135-143
6. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 (2002) 451-455
7. De Valle M.B., Klinteberg V.A., Alem N., et al. Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther 24 (2006) 1187-1195
8. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
9. Chalasani N., Fontana R., Watkins P.B., et al. Drug Induced Liver Injury Network (DILIN) prospective study: initial results. [abstract]. Am J Gastroenterol 101 9 Suppl (2006) S169
10. James O.F. Drugs and the ageing liver. J Hepatol 1 (1985) 431-435
11. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 22 (2002) 145-155
12. Olsson R., Wiholm B.E., Sand C., et al. Liver damage from flucloxacillin, cloxacillin, and dicloxacillin. J Hepatol 15 (1992) 154-161
13. Bjornsson E., and Olsson R. Outcome and prognostic markers in severs drug-induced liver disease. Hepatology 42 (2005) 481-489
14. Snider D.E., and Caras G.H. Isoniazid associated hepatitis deaths: a review of available information. Am Rev Respir Dis 145 (1992) 494-497
15. Ohmori S., Shiraki K., Inoue H., et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology 50 (2003) 1531-1534
16. Ostapowicz G., Samuel G., Larson A.M., et al. Identification of drug-induced liver injury among 307 cases of severe liver injury: a retrospective multi-center study. Hepatology 34 Part 2 Suppl (2001) 454A
17. Vuppalanchi R., Liangpunsakul S., and Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 102 (2007) 558-562
18. Huang Y.-S., Chern H.-D., Su W.-J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculous drug-induced hepatitis. Hepatology 35 (2002) 883-889
19. Rodriguez L.A., Stricker B.H., and Zimmerman H.J. Risk f acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 156 (1996) 1327-1332
20. Hautekeete M.L., Brenard R., Horsmans Y., et al. Liver injury related to amoxicillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 22 (1995) 71-77
21. Fontana R.J., Shakil A.O., Greenson J.K., et al. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 50 (2005) 1785-1790
22. O'Donohue J., Oien K.A., Donaldson P., et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II associations. Gut 47 (2000) 717-720
23. Gresser U. Amoxicillin-clavulinic acid therapy may be associated with severe side effects: review of the literature. Eur J Med Res 6 (2001) 139-149
24. Westphal J.F., and Brogard J.M. Antibacterial and antifungal agents. In: Kaplowitz N., and DeLeve L. (Eds). Drug induced liver disease (2003), Marcel Dekker, New York 471-504
25. Davies M.H., Harrison R.F., Elias E., et al. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 20 (1994) 112-116
26. Wokenstein P., Carriere V., Charue D., et al. A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5 (1995) 255-258
27. Weber W.W., and Hein D.W. N-acetylation pharmacogenetics. Pharmacol Rev 37 (1985) 25-79
28. Rieder M.J. Mechanisms of unpredictable adverse drug reactions. Drug Saf 11 (1994) 196-212
29. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 119 (1969) 300-306
30. Derby L.E., Jick H., Henry D.A., et al. Erythromycin-associated cholestatic hepatitis. Med J Aust 158 (1993) 600-602
31. Dujovne C.A. Liver cell culture toxicity and surfactant potency of erythromycin derivatives. Toxicol Appl Pharmacol 32 (1975) 11-20
32. Villa P., Begue J.-M., and Guillouzo A. Effects of erythromycin derivatives on cultured rat hepatocytes. Biochem Pharmacol 33 (1984) 4098-4101
33. Clay K.D., Hanson J.S., Pope S.D., et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 144 (2006) 415-420
34. Paiva L.A., Wright P.J., and Koff R.S. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 87 (1992) 891-893
35. Stricker B.H., Blok A.P., Claas F.H., et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8 (1988) 599-606
36. Dembry L.M., Farrington J.M., and Andriole V.T. Fluoroquinolone antibiotics: adverse effects and safety profile. Infect Dis Clin Pract 8 (1999) 421-428
37. Stricker B.H., Block A.P., Bronkhorst F.B., et al. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 3 (1986) 399-406
38. Steele M.A., Burk R.F., and DesPrez R.M. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 99 (1991) 465-471
39. Brummer D.L. Isoniazid and liver disease. Ann Intern Med 75 (1971) 643-644
40. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174 (2006) 935-952
41. Williams G.M., and Iatropoulos M.J. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 30 (2002) 41-53
42. Maddrey W.C. Isoniazid-induced liver disease. Semin Liver Dis 1 (1981) 77-84
43. Yew W.W., and Leung C.C. Antituberculous drugs and hepatotoxicity. Respirology 11 (2006) 699-707
44. Mitchell J.R., Thorgeirsson U.P., Black M., et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 18 (1975) 70-79
45. Dickinson D.S., Bailey W.C., Hirschowitz B.I., et al. Risk factors for isoniazid induced liver dysfunction. J Clin Gastroenterol 3 (1981) 271-279
46. Gurumurthy P., Krishnamurthy M.S., Nazareth O., et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 129 (1984) 58-61
47. Huang Y.S., Chern H.D., Su W.J., et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37 (2003) 924-930
48. Sarma G.E., Immanuel C., Kailasam S., et al. Rifampin-induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 133 (1986) 1072-1075
49. Franks A., Binkin N., Snider D., et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 104 (1989) 151-155
50. Byrne J.A., Strautnieks S.S., Mieli-Vergani G., et al. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123 (2002) 1649-1658
51. Meyer L. Side effect of drugs. Volume 4 (1964), Exerpta Medica Foundation, Amsterdam p. 131-44
52. Centers for Disease Control and Prevention, American Thoracic Society. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 50 (2001) 733-735
53. Knobel B., Buyanowsky G., Dan M., et al. Pyrazinamide-induced granulomatous hepatitis. J Clin Gastroenterol 24 (1997) 264-266